Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Sayako Yuda1 · Shigeo Fuji1 · Bipin Savani2 · Katie S. Gatwood2

Received: 28 January 2022 / Accepted: 31 March 2022 / Published online: 11 July 2022
© The Author(s) 2022

Abstract
Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.

Keywords Antiemetics · Hematopoietic cell transplantation

1 Introduction
Nausea and vomiting are common side effects of chemotherapy drugs [1, 2]. There is no doubt that high-dose chemotherapies used as conditioning regimens in hematopoietic stem-cell transplantation (HSCT), especially total body irradiation (TBI) or high-dose cyclophosphamide, have high emetic potential [3–5]. The incidence of chemotherapy-induced nausea and vomiting (CINV) has dramatically decreased with the advent of a variety of antiemetics, such as the new generation 5-hydroxytryptamine3 receptor antagonist (5-HT3RA), the neurokinin-1 receptor antagonist (NK1RA) for highly emetic chemotherapy (HEC), and the addition of antipsychotic agents, such as olanzapine. However, CINV is still a concern in HSCT recipients [6], and can be associated with a substantially impaired quality of life (QoL) and a need for artificial feeding to prevent malnutrition.

1 Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-city, Osaka 5418567, Japan
2 Stem Cell Transplant and Cellular Therapy, Vanderbilt University Medical Center, Nashville, USA

The first proposal for controlling CINV was published in 1997 [7] and has been continuously revised by a variety of cancer societies, including the American Society of Clinical Oncology (ASCO) [8], the Multinational Association of Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO) [9] and the National Comprehensive Cancer Network (NCCN) [10]. Although some guidelines describe antiemetic use in the setting of high-dose chemotherapy for HSCT [8, 9, 11], there is no detailed recommendation on their use in each conditioning regimen, and according to the difference in the severity of CINV among the various regimens. This becomes especially challenging to interpret, as several agents used for HSCT conditioning are labeled as being of low or moderate emetic risk, although this classification is typically based on non-HSCT dosing of these agents [12]. Additionally, it does not account for the use of multiple moderately emetic agents in combination which, in many cases, leads the regimen to be considered highly emetic. Therefore, we expect that the clinical practice of antiemetic prescribing for HSCT differs among different countries/institutions, which means that the compliance with the antiemetic guidelines are not necessarily as high in this field as in non-HSCT setting [13–16]. In this article, we review the published literature and summarize the information to clarify the benefit of antiemetic regimens.
2 Literature Review

A review of the literature reporting on antiemetics in HSCT was conducted. The PubMed database was searched to identify all the articles relating to antiemetics in HSCT.

3 Impact of CINV Control in HSCT on Nutritional Status

CINV control is important for patients who receive any form of chemotherapy, particularly from the viewpoint of maintenance of QoL and prevention of malnutrition after HSCT (Fig. 1a and b) [17–19]. Recent reports which assessed the relationship between patients’ general condition and treatment-related complications in HSCT implied that antiemetic treatment has a significant influence on the clinical course of patients receiving HSCT [20, 21].

One important aim of antiemetics is the maintenance of oral caloric intake after HSCT. Nutritional support during the early phase after HSCT is crucial to maintaining body weight and performance status [21–23]. Artificial feeding, such as enteral nutrition (EN) or parenteral nutrition (PN), is used to maintain the target caloric intake in patients with insufficient oral intake due to nausea or vomiting after HSCT. The presence of nausea or vomiting hampers oral intake, as well as the application of EN after HSCT [22]. Feeding through the gastrointestinal (GI) tract is considered important to facilitate the recovery from GI tract damage and, possibly, to maintain the microbiota status after HSCT [24, 25]. Several studies showed that a balanced intestinal flora affects the human immune system and reduces the risk of graft-versus-host disease (GVHD) [26–28]. Retrospective studies suggested the beneficial impact of EN after HSCT [29–33]. In addition, the use of PN is associated with side effects such as hyperglycemia, infection, and liver dysfunction. As hyperglycemia is reported to be associated with increased gut permeability, poor wound healing, and impaired neutrophil function [34–36], excessive use of PN should be avoided. Though no study directly assessed whether CINV affects the incidence of transplant-related complications and death after HSCT, it is reasonable to provide sufficient antiemetics to prevent nausea and vomiting in patients with HSCT, considering the benefit to maintain adequate oral intake after HSCT.

4 Previous Studies on Antiemetics in HSCT

According to the major guidelines, recommendations on antiemetics in patients who received high-dose chemotherapy before HSCT are limited (Table 1). There is no description of the difference or adjustment according to the type or dose of drugs used for HSCT conditioning regimens. Thus, it is unclear whether we should use the same antiemetics in a classical myeloablative conditioning regimen like cyclophosphamide plus TBI, in a modern myeloablative but reduced-toxicity regimen such as fludarabine plus busulfan or melphalan, and in a reduced-intensity conditioning regimen [8, 9, 11]. It is expected that different antiemetic regimens for each conditioning regimen should be used in clinical practice. While notable developments in HEC management in other fields are addressed in current updates [8, 9, 11], antiemetic strategy in HSCT has not yet been well established. Thus, here we review research featuring the use of antiemetic therapy in HSCT.

5 Emetic Risk of Each Drug Used for Conditioning Regimens in HSCT

Unique chemotherapeutic drugs are used in conditioning regimens for HSCT. The drugs may be used in higher doses or in combination in the setting of HSCT. These factors make it difficult to define the emetic risk of certain drugs used for conditioning regimens. For instance, there are inconsistent recommendations in the guidelines for chemotherapy with busulfan or melphalan. First, there is no recommendation regarding intravenous melphalan in the ASCO/MASCC/ESMO guidelines, but in the NCCN guideline it is classified as of moderate risk [1, 37]. Second, intravenous busulfan is treated as of moderate risk in the ASCO and NCCN guidelines [1], but minimal in the MASCC/ESMO guidelines [37]. Previously, intravenous busulfan was treated as minimal risk in the ASCO guideline. These inconsistencies could be confusing for clinicians who are responsible for the determination of antiemetics regimens for given conditioning regimen protocols.
6 Each antiemetic drug in HSCT

6.1 Prevention of Acute and Delayed Emesis

6.1.1 5-HT3RA

Since the demonstration that granisetron was effective against CINV in HEC in the non-HSCT setting decades ago [38], many researchers conducted clinical trials on administration of 5-HT3RAs in HSCT. As many reports revealed the efficacy and safety of 5-HT3RAs in classical myeloablative conditioning regimens using TBI, 5-HT3RAs are widely applied in the HSCT field [39]. In terms of the type of 5-HT3RA, the superiority of...
particularly in the setting of haploidentical transplantation promised engraftment and increased infection risk [45]. Steroid use in allogeneic transplantation can lead to complications such as its potential immunomodulatory effects. Excessive use of dexamethasone in allogeneic HSCT conditioning regimens with olanzapine. A further complicating factor of the use of palonosetron, in comparison to first-generation 5-HT3RA is still controversial [40], but it is obvious that 5-HT3RAs are safe enough to be used in the HSCT setting [40–42]. Now, 5-HT3RAs have been regarded as a basic part of antiemetic strategy for all HSCT conditioning regimens.

### 6.1.2 Dexamethasone

Dexamethasone is used in almost all cases as a standard component of antiemetics for high-dose chemotherapy for HSCT [1, 39], although the exact mechanism of action of corticosteroids for CINV prevention is unclear.

Though dexamethasone plays a vital role in CINV treatment, the appropriate dose and schedules for dexamethasone remain unidentified. When a higher dose of dexamethasone is used, it can be associated with an increased risk of side effects such as hypertension, glucose intolerance, and others [39]. Challenges to dose-reduction of dexamethasone in HEC or moderate-emetic chemotherapy (MEC) have been reported. Some of the clinical trials on MEC or HEC without cisplatin suggested that the administration of palonosetron, instead of the first-generation 5-HT3RAs, made it possible to decrease the dose of dexamethasone to 8 mg on day 1 and to omit it on subsequent days [43, 44]. Additionally, the NCCN guideline on antiemesis updated in 2018 mentioned that dexamethasone on days 2–4 in HEC can be replaced with olanzapine. A further complicating factor of the use of dexamethasone in allogeneic HSCT conditioning regimens is its potential immunomodulatory effects. Excessive steroid use in allogeneic transplantation can lead to compromised engraftment and increased infection risk [45]. Particularly in the setting of haploidentical transplantation with post-transplant cyclophosphamide, the administration of steroids as antiemetics from the day of HSCT until the administration of cyclophosphamide may compromise the efficacy of post-transplant cyclophosphamide, lead to increased risk of GVHD and, therefore, is generally recommended to be avoided as routine CINV prophylaxis [46].

### 6.2 NK1RA

In the 2000s, NK1RA aprepitant was first introduced as an effective drug against CINV in HEC. It was reported that aprepitant remarkably reduced the incidence of CINV [8, 9, 11]. Many studies on antiemetic strategy in HSCT revealed efficacy and safety of NK-1 inhibitors in a combination of 5-HT3RA and dexamethasone (“triplet”) during the conditioning chemotherapy [47–59]. A randomized placebo-controlled trial on CINV during high-dose chemotherapy in autologous (auto-) or allogeneic (allo-) HSCT reported that complete response rates, defined as no emesis with no or mild nausea, were 81.9% in triplet arm and 65.8% in doublet arm ($P <0.001$) [56]. Percentages of patients with no emesis were 73.3% for aprepitant and 22.5% placebo ($P <0.001$). Schmitt et al. proved the triplet to be effective in preventing CINV caused by high-dose melphalan followed by auto-ASCT administered to patients with multiple myeloma [58]. Complete response rates, defined as no emesis and no rescue therapy within 120 h of melphalan administration, were 58% in the aprepitant and 41% in the placebo arm (odds ratio 1.92 [1.23, 3.00], $P =0.0042$). It was confirmed that the addition of aprepitant was tolerable and did not change the pharmacokinetics and metabolism of calcineurin inhibitors or antineoplastic agents [60–62]. Of note, aprepitant is a moderate inhibitor of CYP3A4 and therefore has drug interaction potential with both chemotherapy and supportive care agents used in HSCT [63]. In particular, based on available evidence, it is recommended to use aprepitant with caution or to avoid regimens containing busulfan and etoposide, as they are metabolized via CYP3A4 [64].

Rolapitant and netupitant are other NK1RA. Phase III trials with these agents showed promising data in HEC [65–67], and the NCCN guideline [11] recommended their use in MEC as well as HEC. However, clinical data on these two NK1RAs in HSCT have not been published.

#### 6.2.1 Olanzapine

While central dopamine receptor antagonists, including antipsychotics, are effective for CINV, they usually cause not only somnolence but also extrapyramidal disorders, such as tremor and akathisia, which reduce the QOL and ADL of patients. The incidence of extrapyramidal disorder has been decreased by using new types of antipsychotics including serotonin-dopamine antagonists (SDA) and multi-acting...
receptor-targeted antipsychotics (MARTA). As olanzapine, an agent classified as MARTA, is potent in controlling CINV [18, 68, 69], the latest guidelines recommend it for the patients with HEC in non-HSCT setting [8, 9, 11]. It is also important to consider that olanzapine causes QTc prolongation and this can have an additive effect with many other therapies used routinely in HSCT.

In recent years, some reports on CINV in HSCT focusing on olanzapine were published [70–73]. The FOND-O trial investigated whether the addition of olanzapine 10 mg on each chemotherapy day and 3 days after the triplet prevents CINV in patients with hematological malignancies under HEC or conditioning therapy for HSCT [73]. While there was no significant difference in terms of prevention of CINV in the early phase, the complete response rate was higher in patients who received olanzapine than in those who did not: 55% versus 26% in the overall assessment period and 60.8% versus 30% in the delayed phase. However, subgroup analysis showed that the addition of olanzapine significantly improved CINV control in the auto-HSCT but not in the allo-HSCT cohort, possibly due to a limited number of cases in the subgroup analysis, which should be determined in larger studies in the future. Nakagaki et al. reported that olanzapine was effective to treat breakthrough CINV [72]. Sixty-two patients enrolled in that study receiving auto- or allo-HSCT following high-dose chemotherapy were administered the standard triplet prophylaxis, with added either first or second-generation 5-HT3 antagonists or olanzapine, as rescue-medication against breakthrough emesis. Both trials concluded that olanzapine was tolerable for HSCT patients and did not affect the engraftment of hematopoietic stem cells.

In summary, standard prophylaxis for CINV in HSCT appears to be the triplet of a 5-HT3RA, an NK1RA, and dexamethasone, even though it is less effective for patients receiving high-dose chemotherapy in HSCT than those with HEC or MEC [74]. Even in HSCT with reduced-intensive conditioning (RIC) regimens, which are usually regarded as having a lower risk for nausea, it is unclear whether we should use antiemetics for HEC or MEC. As only few studies have evaluated antiemetic treatment focusing on a specific conditioning regimen in HSCT [41, 47, 48, 54, 58, 59, 61, 70, 75], more evidence to develop a better antiemetic strategy for each conditioning regimen is needed.

7 Treatment for Breakthrough Emesis

In the absence of specific data, the management of breakthrough emesis in HSCT is similar to that of standard chemotherapy. However, physicians must note that prolonged nausea and vomiting in HSCT are often caused not only by conditioning regimens but also other causes like infection, GVHD, primary disease in the GI tract, or concomitantly used drugs.

In cases with a limited improvement of CINV by pharmacological approaches, some research suggested that refractory emesis was managed by using complementary medicine (CAM), including acupuncture [76] and aromatherapy [77]. It is unclear whether CAM in immune-compromised patients could be safely applied, which should be determined in the setting of HSCT.

8 How to Choose the Antiemetics in HSCT

As mentioned above, the current guidelines for antiemetics in HSCT do not dictate the detailed management recommendations for each conditioning regimen. As summarized in Table 2, doses and schedules of conditioning regimens are much more complicated than those of HEC in the non-HSCT setting. Thus, it is practically difficult to give the ranking of CINV risk to the overall regimen. It must be essential to make sophisticated plans for antiemetics, which are adapted to the respective conditioning regimens.

Since the extent of emesis changes day by day, physicians should reconsider the plan for antiemetics every day. Guidelines recommend that patients with multi-day chemotherapy should be offered antiemetics which are appropriate for the risk of the agents administered on each day and for two to three days after the completion of the regimens [8, 9].

NK1 RA, which is effective for both acute and delayed CINV, should be used to target the days with the highest risk for CINV. However, physicians must keep in mind that the information about drug interaction between antiemetics and chemotherapy agents and therapies for supportive care in HSCT is limited as compared with that in HEC.

Though dexamethasone is one of the most convenient antiemetics for clinical use because of less interaction with cytotoxic drugs, extra use of steroids may be intolerable to some patients because of metabolic disorders, such as hyperglycemia and hypoalbuminemia, which overlaps with side effects from the calcineurin inhibitors. Frequent and prolonged exposure to steroid agents causes immunodeficiency, leading patients to severe infection. Steroid administration before post-transplant cyclophosphamide is avoided as it reduces its effects. The control of emesis in post-transplant cyclophosphamide using 5-HT3RA and NK1RA was reported to be insufficient [78]. Individualization of dexamethasone use must be critical, especially in HSCT.

The study which assessed the beneficial impact of olanzapine is still limited [79]. We need more data to assess the safety and efficacy of olanzapine in combination with other antiemetics in HSCT. It is known that olanzapine also causes metabolic disorders. Studies on HEC reported that some of the patients treated with olanzapine developed hyperglycemia [18, 69].
### Table 2: Emetic risk of conditioning regimens according to guidelines

| Regimens          | Dose                                | Risk category Category as a single agent |
|-------------------|-------------------------------------|----------------------------------------|
| **Standard regimens*** |                                     |                                        |
| Cy/TBI            |                                     |                                        |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| TBI               | 2 Gy × 2/day × 3 days               | High                                   |
| Bu/Cy             |                                     |                                        |
| Bu                | 3.2 mg/kg/day × 4 days              | Moderate                               |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| BEAM              |                                     |                                        |
| BCNU              | 300 mg/m²/day × 1 day               | High                                   |
| VP                | 200 mg/m²/day × 4 days              | Low                                    |
| AraC              | 200 mg/m² × 2/day × 4 days          | Low                                    |
| MEL               | 140 mg/m²/day × 1 day               | Moderate                               |
| MEAM              |                                     |                                        |
| MCNU              | 300 mg/m²/day × 1 day               | High                                   |
| VP                | 200 mg/m²/day × 4 days              | Low                                    |
| AraC              | 200 mg/m² × 2/day × 4 days          | Low                                    |
| MEL               | 140 mg/m²/day × 1 day               | Moderate                               |
| LEED              |                                     |                                        |
| MEL               | 130 mg/m²/day × 1 day               | Moderate                               |
| VP                | 300 mg/m²/day × 3 days              | Low                                    |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| Dexa              | 40 mg/day × 4 days                  | –                                      |
| MEL               | 100 mg/m²/day × 2 days              | Moderate                               |
| Bu/MEL            |                                     |                                        |
| Bu                | 3.2 mg/kg/day × 4 days              | Moderate                               |
| MEL               | 140 mg/m²/day × 1 day               | Moderate                               |
| **Intensified regimens*** |                                 |                                        |
| Cy/TBI/VP         |                                     |                                        |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| TBI               | 2 Gy × 2/day × 3 days               | High                                   |
| VP                | 30–60 mg/m²/day × 1 day             | Low                                    |
| Cy/TBI/AraC       |                                     |                                        |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| TBI               | 2 Gy × 2/day × 3 days               | High                                   |
| AraC              | 2–3 g/m² × 2/day × 2 days           | Moderate                               |
| Cy/TBI/TT         |                                     |                                        |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| TBI               | 2 Gy × 2/day × 3 days               | High                                   |
| TT                | 5 mg/kg/day × 2 days                | Moderate                               |
| Bu/Cy/MEL         |                                     |                                        |
| Bu                | 3.2 mg/kg/day × 4 days              | Moderate                               |
| Cy                | 60 mg/kg/day × 2 days               | High                                   |
| MEL               | 140 mg/m²/day × 1 day               | Moderate                               |
| AraC/TBI          |                                     |                                        |
| AraC              | 3 g/m² × 2/day × 2 days             | Moderate                               |
| TBI               | 2 Gy × 2/day × 3 days               | High                                   |
| VP/TBI            |                                     |                                        |
| VP                | 60 mg/kg/day × 1 days               | High                                   |
Moreover, it is essential to take into account the CINV risks. Previous studies demonstrated that female gender, young age, no history of alcohol consumption, no smoking habit, prior episodes of pregnancy-related morning or motion sickness, and poor performance status are high-risk factors for CINV [80–82]. At the time of planning for antiemetics in HSCT, physicians/pharmacists should reevaluate any CINV which the patients developed during their prior chemotherapy. It is also important to distinguish CINV from symptoms related to other causes, such as side effects by opioids, gastrointestinal infections, gut GVHD, and central nervous system infiltration by malignancy.

9 Conclusion

In summary, the adequate dose and schedule of antiemetics against CINV in HSCT have not been established. Antiemetic strategy in HSCT should be individualized taking into consideration the patients’ characteristics and risk categories of each regimen.

Acknowledgements There is no conflict of interest to declare.

Table 2 (continued)

| Regimens | Dose | Risk category |
|----------|------|---------------|
| TBI | 2 Gy × 2/day × 3 days | High |
| Reduced toxicity regimens* | | |
| Flu/MEL | | |
| Flu | 25 mg/m²/day × 5 days | Minimal |
| MEL | 140 mg/m²/day × 1 day | Moderate |
| Flu/Cy | | |
| Flu | 25 mg/m²/day × 5 days | Minimal |
| Cy | 60 mg/kg/day × 2 day | High |
| Flu/Bu4 | | |
| Flu | 30 mg/m²/day × 6 days | Minimal |
| Bu | 3.2 mg/kg/day × 4 days | Moderate |
| Flu/Bu2 | | |
| Flu | 30 mg/m²/day × 6 days | Minimal |
| Bu | 3.2 mg/kg/day × 2 days | Moderate |

CY cyclophosphamide, TBI total body irradiation, Bu busulfan, BCNU carmustine, V Pete poside, AraC cytarabine, MEL melphalan, MCNU ranimustine, Flu fludarabine
*Listed in the order of emetic risk, highest first

Declarations

Conflict of interest The authors had no conflict of interest to declare.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–97.
2. Smith P, Lavery A, Turkington RC. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management. Best Pract Res Clin Gastroenterol. 2020;48–49: 101691.
3. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a
review of antiemetic regimens. Bone Marrow Transplant. 2008;42(8):501–6.
4. Tendas A, Nicola P, Perrotti A, Dentamaro T, de Fabritiis P, Arcese W. Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Support Care Cancer. 2015;23(8):2211.
5. Tendas A, Sollazzo F, Bruno A, Cupelli L, Nicola P, Pignatelli AC, et al. Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Support Care Cancer. 2012;20(5):891–2.
6. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–9.
7. Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J, et al. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant. 1997;20(6):473–8.
8. Hesseth PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–61.
9. Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–94.
10. Pastore D, Bruno B, Carluccio P, De Candia MS, Mammoliti S, et al. Better outcome of patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Transplantation. 2012;94(3):287–94.
11. Andersen S, Weber N, Kennedy G, Varelias A, Banks M, et al. Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome post-allogeneic transplantation. Br J Haematol. 2020;188(4):570–81.
12. Fuhrer N, Leu S, Vass P, Schmitt MM, Schmidkunz C, et al. Enteral feeding and early outcomes of patients undergoing allogeneic stem cell transplantation following myeloablative conditioning. Transplantation. 2006;82(6):835–9.
13. Seguy D, Duhamel A, Jegou B, Rejeb MB, Gomez E, Buhlf ND, Bruno B, et al. Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation. Transplantation. 2012;94(3):287–94.
14. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 1992;19(5):566–79.
15. Chow R, Chiu L, Navaei R, Passik S, Chiu N, Popovic M, et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016;24(2):1001–8.
16. Tamura K, Iba A, Kaiki T, Nakanishi Y, Kamura T, Baba H, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015;20(5):855–65.
38. Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf. 2003;26(4):227–59.

39. Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, et al. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer. 2019;27(3):793–803.

40. Chou CW, Chen YK, Yu YB, Chang KH, Hwang WL, Teng CL. Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2014;93(7):1225–32.

41. Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011;22(4):939–46.

42. Yeh SP, Lo WC, Hsieh CY, Bai LY, Lin CC, Lin PH, et al. Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2014;22(5):1199–206.

43. Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21(5):1083–8.

44. Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer. 2013;21(2):565–73.

45. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9):2290–300.

46. Saad A, Taneja A, Di Stasi A, Sarmad R, Kukkamalla R, Costa L, et al. Impact of high-dose steroid premedication on the outcome of myeloablative T cell replete haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2018;53(10):1345–8.

47. Pielichowski W, Barzal J, Gawronska K, Mlot B, Oborska S, Wasko-Grabowska A, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc. 2011;43(8):3107–10.

48. Pielichowski W, Gawronska K, Mlot B, Oborska S, Wasko-Grabowska A, Rzepecki P. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J Buon. 2011;16(3):541–6.

49. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract. 2010;16(1):45–51.

50. Bubalo J, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz R. A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2018;53(8):1010–8.

51. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruesse J, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011;46(6):784–9.

52. Uchida M, Kato K, Ikuse H, Ichinose K, Hiraiba H, Sakurai A, et al. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy. 2013;33(9):893–901.

53. Uchida M, Ikuse H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, et al. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull. 2013;36(5):819–24.

54. Sakurai M, Mori T, Kato J, Koda Y, Kikuchi T, Kohashi S, et al. Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2014;99(4):457–62.

55. Nakamura A, Kojima Y, Miyazawa K, Matsumoto S, Iida H, Nagai H. Clinical impact of aprepitant in patients receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation: a cost-effectiveness analysis. Oncology. 2017;93(5):302–8.

56. Stiff PJ, Fox-Giemanent MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013;19(1):49–55.e41.

57. Schmitt T, Goldschmidt H, Neben K, Freiberger A, Husing J, Gronkowski M, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol. 2014;32(30):3413–20.

58. Benson DM Jr, et al. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer. 2014;22(11):2911–6.

59. Saltarelli D, et al. Three palonosetron regimens to prevent CINV in patients with multiple myeloma: a phase II study. Support Care Cancer. 2014;22(11):2895–901.

60. Aapro MS, Walko CM. Aprepitant: drug–drug interactions in perspective. Ann Oncol. 2010;21(12):2316–23.

61. Ibrahim RB, Abidi MH, Ayash LJ, Cronin SM, Cadotte C, Mulawa KD, Mikus G. The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol. 2011;70(6):903–7.

62. Egerer G, Eisenlohr K, Gronkowski M, Burhenne J, Riedel KD, Mikus G. The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol. 2010;70(6):903–7.

63. Ibrahim RB, Abidi MH, Ayash LJ, Cronin SM, Cadotte C, Mulawa KD, Mikus G. The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol. 2010;70(6):903–7.

64. Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2010;70(6):903–7.

65. Egerer G, Eisenlohr K, Gronkowski M, Burhenne J, Riedel KD, Mikus G. The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol. 2010;70(6):903–7.

66. Ibrahim RB, Abidi MH, Ayash LJ, Cronin SM, Cadotte C, Mulawa KD, Mikus G. The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol. 2010;70(6):903–7.
vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328–33.
66. Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340–6.
67. Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16(9):1079–89.
68. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655–63.
69. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–42.
70. Trifilio S, Welles C, Seeger K, Mehta S, Fishman M, McGowan K, et al. Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk. 2017;17(9):584–9.
71. Tendas A, Marchesi F, Annibali O, Saltarelli D, Niscola P, Perrotti AP, et al. Chemotherapy-induced nausea and vomiting prophylaxis in high-dose melphalan and autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2018;18(2):161–2.
72. Nakagaki M, Barras M, Curley C, Butler JP, Kennedy GA. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2017;25(2):607–13.
73. Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant
74. Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2005;13(2):112–6.
75. Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant. 1999;23(3):265–9.
76. Deng YR, Fu CW, Wu T, Huang WP, Nie H, Jiao Y. Acupuncture therapy for preventing the nausea and vomiting following high emetic risk chemotherapy: a protocol for systematic review and Bayesian Network meta-analysis. Medicine (Baltimore). 2020;99(38):e22150.
77. Ndao DH, Ladas EJ, Cheng B, Sands SA, Snyder KT, Garvin JH Jr, et al. Inhalation aromatherapy in children and adolescents undergoing stem cell infusion: results of a placebo-controlled double-blind trial. Psychooncology. 2012;21(3):247–54.
78. Nakashima T, Inamoto Y, Ito A, Tanaka T, Kim SW, Fukuda T, et al. Nausea and vomiting during post-transplantation cyclophosphamide administration. Int J Hematol. 2020;112(4):577–83.
79. Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant. 2018;24(10):2065–71.
80. Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18(9):1171–7.
81. Sekine J, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104(6):711–7.
82. Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19(6):807–13.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.